Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection
Corresponding Author
Francesca Peccerillo
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Correspondence Dr. Peccerillo Francesca, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy. Email: [email protected]Search for more papers by this authorGiulia Odorici
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Search for more papers by this authorGiovanni Pellacani
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Search for more papers by this authorAndrea Conti
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Search for more papers by this authorCorresponding Author
Francesca Peccerillo
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Correspondence Dr. Peccerillo Francesca, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy. Email: [email protected]Search for more papers by this authorGiulia Odorici
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Search for more papers by this authorGiovanni Pellacani
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Search for more papers by this authorAndrea Conti
Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Search for more papers by this author
REFERENCES
- Bonifati, C., Lora, V., Graceffa, D., & Nosotti, L. (2016). Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World Journal of Gastroenterology, 22(28), 6444–6455.
- Di Nuzzo, S., Boccaletti, V., Fantini, C., Cortelazzi, C., Missale, G., Fabrizi, G., … Pagliarello, C. (2016). Are anti-TNF-α agents safe for treating psoriasis in hepatitis C virus patients with advanced liver disease? Case reports and review of the literature. Dermatology, 232(1), 102–106.
- Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, A., … Girolomoni, G. (2017). Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. Journal of European Academy of Dermatology and Venereology, 31(5), 774–790.
- Morisco, F., Guarino, M., La Bella, S., Di Costanzo, L., Caporaso, N., Ayala, F., & Balato, N. (2014). Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterology, 14(1), 214
- Motaparthi, K., Stanisic, V., Van Voorhees, A. S., Lebwohl, M. G., & Hsu, S.; Medical Board of the National Psoriasis Foundation (2014). From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. Journal of American Academy of Dermatology, 70(1), 178–186.
- Papp, K. A., Langley, R. G., Sigurgeirsson, B., Abe, M., Baker, D. R., Konno, P., … Richards, H. B. (2013). Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II doseranging study. British Journal of Dermatology, 168(2), 412–421.
- Piaserico, S., Dapavo, P., Conti, A., Gisondi, P., & Russo, F. P. (2017). Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: A multicentre cohort study of 37 patients and review of the literature. Journal of European Academy of Dermatology and Venereology, 31(11), 1853–1859.
- Prignano, F., Ricceri, F., Pescitelli, L., Zanieri, F., & Lotti, T. (2011). Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: A retrospective analysis of 17 patients. British Journal of Dermatology, 164(3), 645–647.
- Tan, J., Zhou, J., Zhao, P., & Wei, J. (2012). Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clinical Rheumatology, 31(8), 1169–1175.
- Yanagihara, S., Sugita, K., Yoshida, Y., Tsuruta, D., & Yamamoto, O. (2017). Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. European Journal of Dermatology, 27, 185–186.
